- Home
- RGNX
RGNX
REGENXBIO Inc.
as 07-26-2024 4:00pm EST
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as REGENXBIO Inc. RGNX prepares to release earnings report on 01 Aug 2024.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 536.9M | IPO Year: | 2015 |
| Target Price: | $40.50 | AVG Volume (30 days): | 579.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.49 - $28.80 | Next Earning Date: | 08-01-2024 |
| Revenue: | $86,726,000 | Revenue Growth: | -20.90% |
| Revenue Growth (this year): | 22.59% | Revenue Growth (next year): | 160.07% |
Stock Insider Trading Activity of REGENXBIO Inc. (RGNX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mills Kenneth T. | RGNX | President and CEO | May 14 '24 | Sell | $15.81 | 15,000 | $237,222.00 | 408,035 | SEC Form 4 |
| Mills Kenneth T. | RGNX | President and CEO | Apr 15 '24 | Sell | $18.19 | 15,000 | $272,871.00 | 408,035 | SEC Form 4 |
| Mills Kenneth T. | RGNX | President and CEO | Mar 14 '24 | Sell | $21.86 | 15,000 | $327,942.00 | 408,035 | SEC Form 4 |
| PAKOLA STEVE | RGNX | Chief Medical Officer | Mar 5 '24 | Sell | $28.36 | 12,878 | $365,220.08 | 107,192 | SEC Form 4 |
| Mills Kenneth T. | RGNX | President and CEO | Feb 14 '24 | Sell | $16.47 | 4,652 | $76,625.88 | 418,383 | SEC Form 4 |
| Mills Kenneth T. | RGNX | President and CEO | Feb 14 '24 | Sell | $16.88 | 10,348 | $174,722.88 | 408,035 | SEC Form 4 |
| Mills Kenneth T. | RGNX | President and CEO | Jan 16 '24 | Sell | $15.18 | 45,000 | $682,992.00 | 408,035 | SEC Form 4 |
| PAKOLA STEVE | RGNX | Chief Medical Officer | Jan 2 '24 | Sell | $17.39 | 17,237 | $299,789.35 | 107,192 | SEC Form 4 |
Latest REGENXBIO Inc. News
RGNX Breaking Stock News: Dive into RGNX Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights
Argus Research
3 days ago
RGNX: What does Argus have to say about RGNX?
Argus Research
10 days ago
RGNX: Raising target price to $14.00
Zacks
14 days ago
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Argus Research
17 days ago
RGNX: What does Argus have to say about RGNX?
Zacks
18 days ago
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Argus Research
24 days ago
RGNX: Lowering target price to $11.00
Insider Monkey
a month ago
Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?
Compare RGNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGNX REGENXBIO Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.